Annovis Bio CEO to Present at Meridian Clinical Trials Summit

Rhea-AI Summary

Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Dr. Maria Maccecchini, will present at the Meridian Clinical Trials Summit on November 2, 2020. Her presentation will focus on strategies for de-risking Phase 3 clinical studies using insights from ongoing Phase 2a trials for Alzheimer's and Parkinson's diseases. Dr. Maccecchini aims to demonstrate how the lead compound, ANVS401, can potentially reverse toxic neural effects and restore brain function. The company is developing therapies targeting multiple neurotoxic proteins to improve cognitive and bodily functions affected by these diseases.

Positive

• Dr. Maccecchini is presenting at a significant clinical summit, highlighting the company's involvement in the clinical trial community.
• ANVS401 is positioned as a potential therapeutic solution targeting multiple neurotoxic proteins.
• Ongoing Phase 2a studies show commitment to advancing clinical research in Alzheimer's and Parkinson's diseases.

Negative

• None.

BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its Founder and CEO, Maria Maccecchini, Ph.D., is presenting at the Meridian Clinical Trials Summit on November 2, 2020 at 10 a.m. ET.

Dr. Maccecchini’s presentation, “De-risking Phase 3 clinical studies in Phase 2; case study from Alzheimer’s and Parkinson’s”, will share insight learned from the Company’s ongoing clinical studies which are measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401, the Company’s lead compound, might reverse the toxic cascade and recover normal brain function.

“I look forward to sharing with the attendees how I believe we are effectively de-risking our clinical trial programs through our current Phase 2a studies,” commented, Dr. Maccecchini.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

SOURCE: Annovis Bio, Inc.

FAQ

What is the focus of Annovis Bio's presentation at the Meridian Clinical Trials Summit?

Dr. Maria Maccecchini's presentation will focus on de-risking Phase 3 clinical studies based on insights from ongoing Phase 2a trials for Alzheimer's and Parkinson's diseases.

What is ANVS401 and what diseases does it target?

ANVS401 is Annovis Bio's lead compound aimed at addressing neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease, by targeting multiple neurotoxic proteins.

When is Annovis Bio's presentation scheduled?

Annovis Bio's presentation is scheduled for November 2, 2020, at 10 a.m. ET.

What are the expected outcomes of the Phase 2a studies for Annovis Bio?

The Phase 2a studies aim to measure the potential of ANVS401 to reverse toxic neural effects and improve brain function.

What does de-risking Phase 3 studies imply for Annovis Bio?

De-risking Phase 3 studies implies that the company aims to mitigate potential risks associated with these trials by gathering comprehensive data from earlier Phase 2 studies.